Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 18, 2017 - Issue 12
Submit an article Journal homepage
372
Views
12
CrossRef citations to date
0
Altmetric
Review

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings

Natalie UySection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USAView further author information
,
Abhay SinghSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USAView further author information
,
Steven D. GoreSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USAView further author information
&
Thomas PrebetSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-6872-625XView further author information
ORCID Icon
Pages 1213-1224 | Received 26 Apr 2017, Accepted 27 Jun 2017, Published online: 01 Aug 2017

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Eytan M. Stein, Gaetano Bonifacio, Dominick Latrémouille-Viau, Sherry Shi, Annie Guérin, Eric Q. Wu, Islam Sadek & Xiting Cao. (2021) Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Journal of Medical Economics 24:1, pages 234-243.
Read now

Articles from other publishers (11)

Amer M Zeidan, Kiyoshi Ando, Odile Rauzy, Mehmet Turgut, Ming-Chung Wang, Roberto Cairoli, Hsin-An Hou, Yok-Lam Kwong, Montserrat Arnan, Stef Meers, Vinod Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Julie Niolat, Pedro Marques Ramos, Hans D Menssen, Pierre Fenaux, Yasushi Miyazaki & Uwe Platzbecker. (2023) Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Haematology.
Crossref
Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steve Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia‐Manero, Norbert Vey, Martin Wermke, Jeroen J. W. M. Janssen, Rupa Narayan, Shaun Fleming, Sun Loo, Natalia Tovar, Mika Kontro, Oliver G. Ottmann, Purushotham Naidu, Haiying Sun, May Han, Roisin White, Na Zhang, Anisa Mohammed, Catherine A. Sabatos‐Peyton, David P. Steensma, Mikael L. Rinne, Uma M. Borate & Andrew H. Wei. (2023) Phase Ib study of sabatolimab ( MBG453 ), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes . American Journal of Hematology.
Crossref
José Guilherme de Almeida, Emma Gudgin, Martin Besser, William G. Dunn, Jonathan Cooper, Torsten Haferlach, George S. Vassiliou & Moritz Gerstung. (2023) Computational analysis of peripheral blood smears detects disease-associated cytomorphologies. Nature Communications 14:1.
Crossref
Abhay Singh & Hetty E. Carraway. (2023) Overview of the Management of Higher-Risk Myelodysplastic Syndromes. The Cancer Journal 29:3, pages 160-167.
Crossref
Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle & Valeria Santini. (2023) STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future Oncology 19:9, pages 631-642.
Crossref
Pauline P. Frank, Mabel X. E. Lu & Emma C. Sasse. (2022) Educational and Emotional Needs of Patients with Myelodysplastic Syndromes: An AI Analysis of Multi-Country Social Media. Advances in Therapy 40:1, pages 159-173.
Crossref
Uma M. Borate. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine 1 20 .
Anson Snow & Joshua F. Zeidner. (2022) The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?. Therapeutic Advances in Hematology 13, pages 204062072211128.
Crossref
Shukaib Arslan, Samer Khaled & Ryotaro Nakamura. 2021. Biology and Treatment of Leukemia and Bone Marrow Neoplasms. Biology and Treatment of Leukemia and Bone Marrow Neoplasms 115 132 .
Jan Philipp Bewersdorf, Hetty Carraway & Thomas Prebet. (2020) Emerging treatment options for patients with high-risk myelodysplastic syndrome. Therapeutic Advances in Hematology 11, pages 204062072095500.
Crossref
Roberto Castelli, Riccardo Schiavon & Giorgio Lambertenghi Deliliers. (2018) The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes. Medical Oncology 35:3.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.